News Release

Grafts against cancer

A major discovery to identify 'dangerous donors' in advance

Peer-Reviewed Publication

University of Montreal

A research team led by Prof. Claude Perreault, Université de Montréal, is announcing a major discovery in Genomics. This will generate a fundamental impact on the treatment of blood cancers (leukemias and lymphomes) by means of peripheral blood T-cell grafts.

Peripheral blood stem-cell grafts from immunologically-matched donors are still the best way to treat or cure patients with certain leukemias and lymphomas. In Canada alone, 10 000 people have benefited from this therapy. However, this type of graft is risky because of a major potential complication: "graft-versus-host disease" (GVHD). GVHD is a rejection of recipient tissues by the donor's T cells that see their new host as ‘non-self'. As many as 60% of recipients develop GVHD. In the best-case GVHD scenario, the disease markedly diminishes the patient's quality of life. In the most severe cases, GVHD may cause death. Because of the GVHD risk, graft of donor T cells can only be proposed to a small number of patients having leukemia or lymphoma. And until now, no reliable prediction could be made to determine if a recipient would be likely to incur GVHD or not. Published this week in the Public Library of Science Medicine (PLoS Medicine) this discovery provides a sure way of identifying cells that will cause GVHD.

Today's announced discovery opens the way to a reliable test to determine whether or not the cells of a donor will likely cause GVHD or not in the recipient, if the graft is performed. Creating a predictive test based on this discovery will have a considerable impact on the future of patients.

"A predictive test that will identify dangerous and non-dangerous donors will allow physicians to choose the best donor," explains Dr Perreault. "If no ‘non-dangerous donor' is found, then a physician can give the recipient a more intensive immuno-suppressive treatment to prevent GVHD. This opens the door to hematopoietic cell transplant personalized medicine."

"In this research, the special combinations of clinical design, advanced cell-sorting technology, large-scale gene expression profiling, and novel statistically-supported outcome-predictive computational analyses have produced together a very effective systems biology approach," says Biosystemix co-founder Dr. Larry Greller. "We are excited by the practicality and potential medical utility of these results, and look forward to their continuing validation in larger contexts," says Biosystemix co-founder Dr. Roland Somogyi.

For Génome Québec, it is a truly dramatic breakthrough that will not only improve and save lives, but also highlights the importance of backing and promoting knowledge in Genomics. According to Paul L'Archevêque, President and CEO of Génome Québec, "The researchers have done tremendous work! Clinical work will be transformed and moreover, first-line needs will be met in hospitals, from bench to bedside.".

The study involved 13 senior researchers and 50 patients suffering from haematological cancers and their respective immunologically-matched sibling donors. The patients were from the Maisonneuve-Rosemont hospital in Montreal. Statistical analysis and mathematical outcome-predictive modeling of these complex data were provided by the biotech company Biosystemix Ltd. In the coming months, the discovery will be extended in larger test phases to other hospitals in Canada and the US.


This research project was possible thanks to the financial help of Génome Québec, Génome Canada, The Dana Foundation (New York) and the Fonds de recherche en santé du Québec (FRSQ).

About the IRIC

The IRIC is a major, systems biology based cross-disciplinary research centre dedicated to immunology and cancer. It is led by a group of internationally-recognized scientists and engages in ambitious collaborations involving complementary fields of expertise to tackle some of the greatest obstacles to human health. IRIC was inaugurated at the heart of the Université de Montréal campus in spring 2005 and is expected to double in size over the coming years, for a total of over 500 investigators, postdoctoral fellows, graduate students and professionals by the end of the decade. For more information, visit our website at:

About Génome Québec

Génome Québec's core mission is to mobilize scientists and industries towards research in Genomics and Proteomics. This non-profit private organization invests and manages more than 380M$ from both public & private sector. Génome Québec is currently leading into six domains: human health, bioinformatics, ethics, environment, forest sciences and agriculture. To learn more on Génome Québec and genomics, see our Website:


Génome Québec :
Evelyn Dubois, Huguette Marcotte - Communications
Telephone : (514) 527-3983 ; cellular : (514) 770-3983 ;

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.